Neuphoria Therapeutics Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveOct 5 →Insiders2 insiders bought $3.3M in 1 open-market buy. No sales.→HoldersLynx1 16.2%AdvisorShares Investments 4.7%Vanguard 3.2%→Financing →PeersClosest companies: RAPP, ANRO, MBX→
From the filings
Figures
- Revenue
- $1.2Mlast 12 months
- Net income
- −$13.5Mlast 12 months
- Operating cash flow
- −$12.4Mlast 12 months
- Cash and equivalents
- $19.9Mat the last balance sheet
- Shares outstanding
- 5.4M shareson issue